A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors.

被引：1
|
作者：
Infante, Jeffrey R.
Naing, Aung
Papadopoulos, Kyriakos P.
Autio, Karen A.
Ott, Patrick Alexander
Wong, Deborah Jean Lee
Falchook, Gerald Steven
Patel, Manish R.
Pant, Shubham
Whiteside, Melinda
Bendell, Johanna C.
Bauer, Todd Michael
Janku, Filip
Javle, Milind M.
Hong, David S.
Oft, Martin
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] START Ctr Canc Care, San Antonio, TX USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Sarah Cannon Res Inst HealthONE, Denver, CO USA
[8] Sarah Cannon Res Inst Florida Canc Specialists, Sarasota, FL USA
[9] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA
[10] ARMO BioSci, Redwood City, CA USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3017
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors.
    Xu, Rui-hua
    Qiu, Miao-Zhen
    Zhang, Yang
    Wei, Xiao-Li
    Hu, Chaohong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [46] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [47] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [48] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A first-in-human phase dose-escalation study of YH002, a recombinant humanized agonistic anti-OX40 IgG1 monoclonal antibody, in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Wilkinson, Kate
    Park, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345